MBManuel Battegay

Manuel Battegay

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Manuel Battegay has a total of 43 co-authors. Here are the top co-authors by number of shared publications:

  • Andreas Franz Widmer

    University Hospital Basel

    3 shared publications
  • Dominik Mertz

    Department of Clinical Epidemiology and Biostatistics, McMaster University, MDCL 3200, 1200 Main Street West, Hamilton, ON, L8N 3Z5, Canada,

    2 shared publications
  • Reno Frei

    Division of Clinical Microbiology, University Hospital Basel, Basel, Switzerland

    2 shared publications
  • Ursula Fluckiger

    University Hospital Basel, Division of Infectious Diseases and Hospital Epidemiology, Basel, Switzerland,1 University Hospital Basel, Hematology Department, Basel, Switzerland,2 University of Wuerzburg, Institute for Molecular Infection Biology, Wuerzburg, Germany,3 The Queen's University of Belfast, Centre for Infection & Immunity, Belfast, United Kingdom,4 University Hospital Basel, Laboratory of Microbiology, Basel, Switzerland5

    2 shared publications
  • A. Holbro

    University Hospital Basel

    1 shared publication
  • B. Khanlari

    Klinik für Infektiologie und Spitalhygiene, Universitätsspital Basel, Petersgraben 4, 4031 Basel

    1 shared publication

Latest Publications

  • Open Access

    Is switching to an oral antibiotic regimen safe after 2 weeks of intravenous treatment for primary bacterial vertebral osteomyelitis?

    by Baharak Babouee Flury, Luigia Elzi, Marko Kolbe, Reno Frei, Maja Weisser, Stefan Schären, Andreas F Widmer, Manuel Battegay

    Vertebral osteomyelitis (VO) may lead to disabling neurologic complications. Little evidence exists on optimal antibiotic management.


  • Eradication of an epidemic methicillin-resistant Staphylococcus aureus (MRSA) from a geriatric university hospital: evidence from a 10-year follow-up

    by D. Mertz, R. Frei, N. Periat, C. Scheidegger, M. Battegay, W. Seiler, A. F. Widmer

    We report on a successful eradication of methicillin-resistant S. aureus (MRSA) after an epidemic in 1992 in the geriatric ward of a tertiary-care hospital. After identification of MRSA in seven patients, all patients and staff members in the geriatric ward underwent screening. A multifaceted intervention plan was implemented: contact isolation, optimization of infection control and decolonization of all MRSA carriers. Thirty-two patients and five staff members were found to be MRSA carriers. Twenty one of 32 (66%) patients and all five staff members were successfully decolonized. Seven of 32 (22%) patients died during the epidemic before decolonization. A couple was discharged with persisting MRSA colonization and two individuals were lost to follow-up. The eradication of the epidemic clone was proven by systematic screenings in 1995 and 1997. Since then, the strain has no longer been identified in our institution, based on epidemiological surveillance and molecular typing of all MRSA strains obtained from any specimen. This study provides strong evidence that long-term eradication of an MRSA epidemic in a hospital is feasible, and endemicity of MRSA after an outbreak can be avoided. The successful bundle approach for eradication of MRSA during an epidemic is expensive, but the long-term benefits likely outweigh the initial heavy use of resources.


  • Open Access

    Appropriateness of antibiotic treatment in intravenous drug users, a retrospective analysis

    by Dominik Mertz, Nina Viktorin, Marcel Wolbers, Gerd Laifer, Bernd Leimenstoll, Ursula Fluckiger, Manuel Battegay

    Background: Infectious disease is often the reason for intravenous drug users being seen in a clinical setting. The objective of this study was to evaluate the appropriateness of treatment and outcomes for this patient population in a hospital setting. Methods: Retrospective study of all intravenous drug users hospitalized for treatment of infectious diseases and seen by infectious diseases specialists 1/2001–12/2006 at a university hospital. Treatment was administered according to guidelines when possible or to alternative treatment program in case of patients for whom adherence to standard protocols was not possible. Outcomes were defined with respect to appropriateness of treatment, hospital readmission, relapse and mortality rates. For statistical analysis adjustment for multiple hospitalizations of individual patients was made by using a generalized estimating equation. Results: The total number of hospitalizations for infectious diseases was 344 among 216 intravenous drug users. Skin and soft tissue infections (n = 129, 37.5% of hospitalizations), pneumonia (n = 75, 21.8%) and endocarditis (n = 54, 15.7%) were most prevalent. Multiple infections were present in 25%. Treatment was according to standard guidelines for 78.5%, according to an alternative recommended program for 11.3%, and not according to guidelines or by the infectious diseases specialist advice for 10.2% of hospitalizations. Psychiatric disorders had a significant negative impact on compliance (compliance problems in 19.8% of hospitalizations) in multiple logistic regression analysis (OR = 2.4, CI 1.1–5.1, p = 0.03). The overall readmission rate and relapse rate within 30 days was 13.7% and 3.8%, respectively. Both non-compliant patient behavior (OR = 3.7, CI 1.3–10.8, p = 0.02) and non-adherence to treatment guidelines (OR = 3.3, CI 1.1–9.7, p = 0.03) were associated with a significant increase in the relapse rate in univariate analysis. In 590 person-years of follow-up, 24.6% of the patients died: 6.4% died during hospitalization (1.2% infection-related) and 13.6% of patients died after discharge. Conclusion: Appropriate antibiotic therapy according to standard guidelines in hospitalized intravenous drug users is generally practicable and successful. In a minority alternative treatments may be indicated, although associated with a higher risk of relapse.


  • Mycobacterium-avium-Pneumonie bei HIV-negativem Patienten

    by B. Khanlari, E. Burri, F. Mihatsch, U. Flückiger, M. Battegay

    Ein 79-jähriger Patient mit kurativ behandeltem Lungenkarzinom wurde wegen Fieber, Atemnot und Husten zugewiesen. Eine Antibiotikatherapie zur Pneumoniebehandlung brachte keine Besserung, und radiologisch war die Pneumonie progredient. Ein Erreger konnte nicht gefunden werden. Erst unter einer Steroidtherapie bei vermuteter kryptogener Pneumonitis normalisierten sich die Entzündungszeichen und die Symptomatik war rückläufig. Nach 3-wöchiger Kultivierung konnten im Eintrittssputum Mycobacterium avium Complex (MAC) gefunden und eine MAC-Pneumonie diagnostiziert werden. A 79-year-old patient was admitted with fever and shortness of breath. His medical history included treatment for lung cancer 3 years previously. The patient’s clinical and radiological status remained unchanged despite antibiotic treatment for pneumonia. No infectious pathogen could be identified. Treatment with systemic steroids for suspected cryptogenic organizing pneumonitis (COP) was started. Following steroid treatment the patient’s shortness of breath ameliorated and C-reactive protein was normal. Three weeks after admission Mycobacterium avium complex (MAC) grew in sputa cultures and therefore a diagnosis of MAC pneumonia was made.


  • Open Access

    Empirical use of antibiotics and adjustment of empirical antibiotic therapies in a university hospital: a prospective observational study

    by Julian Mettler, Mathew Simcock, Pedram Sendi, Andreas F Widmer, Roland Bingisser, Manuel Battegay, Ursula Fluckiger, Stefano Bassetti

    Background: Several strategies to optimise the use of antibiotics have been developed. Most of these interventions can be classified as educational or restrictive. Restrictive measures are considered to be more effective, but the enforcement of these measures may be difficult and lead to conflicts with prescribers. Any intervention should be aimed at targets with the highest impact on antibiotic prescribing. The aim of the present study was to assess the adequacy of empirical and adjusted antibiotic therapies in a Swiss university hospital where no antibiotic use restrictions are enforced, and to identify risk factors for inadequate treatment and targets for intervention. Methods: A prospective observational study was performed during 9 months. All patients admitted through the emergency department who received an antibiotic therapy within 24 hours of admission were included. Data on demographic characteristics, diagnoses, comorbidities, systemic inflammatory response syndrome (SIRS) parameters, microbiological tests, and administered antibiotics were collected prospectively. Antibiotic therapy was considered adequate if spectrum, dose, application modus, and duration of therapy were appropriate according to local recommendations or published guidelines. Results: 2943 admitted patients were evaluated. Of these, 572 (19.4%) received antibiotics within 24 hours and 539 (94%) were analysed in detail. Empirical antibiotic therapy was inadequate in 121 patients (22%). Initial therapy was adjusted in 168 patients (31%). This adjusted antibiotic therapy was inadequate in 46 patients (27%). The main reason for inadequacy was the use of antibiotics with unnecessarily broad spectrum (24% of inadequate empirical, and 52% of inadequate adjusted therapies). In 26% of patients with inadequate adjusted therapy, antibiotics used were either ineffective against isolated pathogenic bacteria or antibiotic therapy was continued despite negative results of microbiological investigations. Conclusion: The rate of inadequate antibiotic therapies was similar to the rates reported from other institutions despite the absence of a restrictive antibiotic policy. Surprisingly, adjusted antibiotic therapies were more frequently inappropriate than empirical therapies. Interventions aiming at improving antibiotic prescribing should focus on both initial empirical therapy and streamlining and adjustment of therapy once microbiological results become available.


  • Genotypic and phenotypic resistance testing of HIV-1 in routine clinical care

    by H. H. Hirsch, H. Drechsler, A. Holbro, F. Hamy, P. Sendi, K. Petrovic, T. Klimkait, M. Battegay

    Data on genotypic and phenotypic resistance testing of HIV-1 in the routine clinical setting are lacking. In a retrospective single-center study, all patients (n=102) for whom genotypic resistance typing (GRT) and phenotypic resistance typing (PRT) were performed during the calendar year 2002 were examined. GRT and PRT results were concordant for 79% of the drugs, being highest for nevirapine (92%) and lowest for didanosine (57%). Concordance of results for protease inhibitors was lowest for lopinavir (78%) and highest for indinavir (88%). Discordant results for lamivudine were observed in 16% of patients; 90% of these results corresponded to high-level resistance by PRT and susceptibility by GRT. Overall, HIV loads were lower and CD4+ cell counts higher after therapy following resistance testing, but a significant association with the number of active drugs as predicted by GRT or PRT could not be identified. In a subgroup of 43 patients with virological failure under antiretroviral therapy and sufficient follow-up data, HIV loads were significantly lower after 3 and 6 months. More patients with HIV loads p=0.109. This was also found for HIV loads p=0.103), although the differences were not statistically significant. There was no discernable difference between GRT and PRT in the clinic-based population, but the numbers of resistance tests performed are not sufficient to draw definitive conclusions.


  • Open Access

    Characteristics, Determinants, and Clinical Relevance of CD4 T Cell Recovery to <500 Cells/ L in HIV Type 1--Infected Individuals Receiving Potent Antiretroviral Therapy

    by Gilbert R. Kaufmann, Hansjakob Furrer, Bruno Ledergerber, Luc Perrin, Milos Opravil, Pietro Vernazza, Matthias Cavassini, Enos Bernasconi, Martin Rickenbach, Bernard Hirschel, et al.

    Background. The CD4 T cell count recovery in human immunodeficiency virus type 1 (HIV-1)—infected individuals receiving potent antiretroviral therapy